IQVIA (NYSE:IQV) Hits New 12-Month Low - Here's What Happened

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report)'s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $169.37 and last traded at $176.28, with a volume of 2234715 shares. The stock had previously closed at $177.39.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IQV. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Finally, StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Five investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Stock Performance

The company has a market capitalization of $27.26 billion, a PE ratio of 20.62, a PEG ratio of 1.99 and a beta of 1.46. The firm has a 50-day moving average of $189.67 and a two-hundred day moving average of $203.82. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $223,000. Captrust Financial Advisors increased its stake in IQVIA by 30.8% during the 3rd quarter. Captrust Financial Advisors now owns 8,188 shares of the medical research company's stock worth $1,940,000 after buying an additional 1,927 shares in the last quarter. Benjamin Edwards Inc. acquired a new position in shares of IQVIA during the third quarter valued at approximately $261,000. Hilltop Holdings Inc. purchased a new position in shares of IQVIA in the third quarter valued at approximately $446,000. Finally, HighTower Advisors LLC boosted its stake in shares of IQVIA by 6.3% in the third quarter. HighTower Advisors LLC now owns 142,031 shares of the medical research company's stock worth $33,640,000 after acquiring an additional 8,436 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.